https://pipelinereview.com/blincyto-blinatumomab-added-to-consolidation-chemotherapy-significantly-improves-survival-in-adult-patients-with-measurable-residual-disease-negative-b-lineage-acute-lymphoblastic-leukemia-b-all/
Blincyto® (blinatumomab) added to consolidation chemotherapy significantly improves survival in adult patients with measurable residual disease-negative B-lineage Acute Lymphoblastic Leukemia (B-ALL)